Asembia
Smart Strategies Needed for Pharma Industry at Time of Unprecedented Changes
The pharmaceutical industry is at the precipice of major change, where market forces are more complex than ever ...
JULY 18, 2023
Utilization Management Important to Control Rare Disease Costs
The number and range of products for rare diseases has challenged payors to balance patient access to innovative ...
MAY 5, 2023
Specialty Dominating 2023 Pipeline
There's been about 15 total FDA drugs approved this year. Of those 12 have been specialty, so over 80% of these ...
MAY 5, 2023
Many Patients Will Still Need Financial Assistance Even With Inflation Reduction Act Drug Price Caps
Even after the Inflation Reduction Act’s out-of-pocket drug spending caps kick in for Medicare beneficiaries, ...
MAY 4, 2023
Health Companies Need to Embrace Consumerism in Their Outreach Strategies
Thinking about patients as consumers of healthcare is a leading trend in medicine today, speakers said during ...
MAY 3, 2023
URAC-HOSP Partnership to Focus on Specialty Pharmacy, Telehealth Accreditation
A new partnership between HOSP and URAC will help make specialty pharmacy and telehealth accreditations more ...
MAY 4, 2022
2017 in Review: Fighting for the Specialty Market & Pt Journey
Every year a 2012 statement made by Phil Hagerman, RPh, the CEO at Diplomat, becomes a little truer: Specialty is ...
DECEMBER 30, 2017
Can Employers Move the Needle On Drug Costs?
Everyone from Congress to patients is making a fuss about the cost of specialty drugs, but it’s the employers ...
MAY 17, 2017
Oncology Top Challenge for Payors
Oncology dominated the key findings of the behemoth annual EMD Serono Specialty Digest report, released Monday, May ...
MAY 2, 2017
Employers: Players Big Enough to Change SP Costs?
The real payors are the employers, with roughly 160 million commercial lives on their rosters.
MAY 2, 2017
